University of South Carolina

Scholar Commons
Faculty Publications

Pharmacy, College of

4-23-2020

Pharmacist-Driven Culture and Sexually Transmitted Infection
Testing Follow-Up Program in the Emergency Department
Stephanie C. Shealy
Christine Alexander
Tina Grof Hardison
Joseph Magagnoli
Julie Ann Justo
justoj@cop.sc.edu

See next page for additional authors

Follow this and additional works at: https://scholarcommons.sc.edu/phar_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons

Publication Info
Published in Pharmacy, Volume 8, Issue 2, 2020, pages 72-.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/).

This Article is brought to you by the Pharmacy, College of at Scholar Commons. It has been accepted for inclusion
in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

Author(s)
Stephanie C. Shealy, Christine Alexander, Tina Grof Hardison, Joseph Magagnoli, Julie Ann Justo, Caroline
Derrick, Joseph Kohn, Hana Rac Winders, Troy Privette, Majdi N. Al-Hasan, and P. Brandon Bookstaver

This article is available at Scholar Commons: https://scholarcommons.sc.edu/phar_facpub/13

pharmacy
Article

Pharmacist-Driven Culture and Sexually Transmitted
Infection Testing Follow-Up Program in the
Emergency Department
Stephanie C. Shealy 1,2 , Christine Alexander 1 , Tina Grof Hardison 1 , Joseph Magagnoli 2 ,
Julie Ann Justo 1,2 , Caroline Derrick 3 , Joseph Kohn 1 , Hana Rac Winders 2 , Troy Privette 4 ,
Majdi N. Al-Hasan 3 and P. Brandon Bookstaver 1,2, *
1

2
3
4

*

Department of Pharmacy, Prisma Health Richland Hospital, Columbia, SC 29203, USA;
shealysc@email.sc.edu (S.C.S.); christine.alexander@prismahealth.org (C.A.);
tina.hardison@prismahealth.org (T.G.H.); justoj@cop.sc.edu (J.A.J.); joseph.kohn@prismahealth.org (J.K.)
Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy,
Columbia, SC 29208, USA; magagnol@mailbox.sc.edu (J.M.); hwinders@cop.sc.edu (H.R.W.)
Department of Medicine, University of South Carolina School of Medicine, Columbia, SC 29209, USA;
caroline.derrick@uscmed.sc.edu (C.D.); majdi.alhasan@uscmed.sc.edu (M.N.A.-H.)
Emergency Department, Prisma Health Richland Hospital, Columbia, SC 29203, USA; priv@aol.com
Correspondence: bookstaver@cop.sc.edu

Received: 11 March 2020; Accepted: 21 April 2020; Published: 23 April 2020




Abstract: Expanding pharmacist-driven antimicrobial stewardship efforts in the emergency
department (ED) can improve antibiotic management for both admitted and discharged patients.
We piloted a pharmacist-driven culture and rapid diagnostic technology (RDT) follow-up program
in patients discharged from the ED. This was a single-center, pre- and post-implementation, cohort
study examining the impact of a pharmacist-driven culture/RDT follow-up program in the ED. Adult
patients discharged from the ED with subsequent positive cultures and/or RDT during the pre(21 August 2018–18 November 2018) and post-implementation (19 November 2018–15 February
2019) periods were screened for inclusion. The primary endpoints were time from ED discharge to
culture/RDT review and completion of follow-up. Secondary endpoints included antimicrobial agent
prescribed during outpatient follow-up, repeat ED encounters within 30 days, and hospital admissions
within 30 days. Baseline characteristics were analyzed using descriptive statistics. Time-to-event data
were analyzed using the Wilcoxon signed-rank test. One-hundred-and-twenty-seven patients were
included, 64 in the pre-implementation group and 63 in the post-implementation group. There was
a 36.3% reduction in the meantime to culture/RDT data review in the post-implementation group
(75.2 h vs. 47.9 h, p < 0.001). There was a significant reduction in fluoroquinolone prescribing in the
post-implementation group (18.1% vs. 5.4%, p = 0.036). The proportion of patients who had a repeat
ED encounter or hospital admission within 30 days was not significantly different between the preand post-implementation groups (15.6 vs. 19.1%, p = 0.78 and 9.4% vs. 7.9%, p = 1.0, respectively).
Introduction of a pharmacist culture and RDT follow-up program in the ED reduced time to data
review, time to outpatient intervention and outpatient follow-up of fluoroquinolone prescribing.
Keywords:
pharmacy resident;
antimicrobial stewardship

rapid diagnostic technology;

urinary tract infections;

1. Introduction
In 2017, the Joint Commission established the requirement for hospitals and nursing homes to
have an antimicrobial stewardship program (ASP) [1]. Although ASPs have been primarily focused in
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the inpatient setting, evidence demonstrates that these programs can reduce unnecessary antimicrobial
prescriptions and improve timely antimicrobial selection in the outpatient setting, including in the
emergency department (ED) [2,3]. Optimized antimicrobial use has been widely associated with
improved clinical outcomes and reduced adverse drug events (ADEs), including Clostridioides difficile
infection [4–6].
Incorporation of a stewardship pharmacist into culture and sexually transmitted infection (STI)
testing follow-up may be an effective method for ASP and pharmacy service expansion to the outpatient
setting [7–13]. In addition to improved antimicrobial selection, culture follow-up programs that involve
a pharmacist have been shown to reduce subsequent ED visits and reduce the time to result review
and patient notification when compared to programs without a pharmacist [7–9,13]. The introduction
of rapid diagnostic technology (RDT) for routine bacterial cultures and STIs has provided another
pathway for early intervention in discharged patients [14,15]. Although guidelines recommend empiric
treatment for suspected STIs, patients may require outpatient follow-up if the empiric treatment
was not appropriate based on the STI result or if the patient was not empirically treated due to low
suspicion [16]. Pharmacist involvement in outpatient follow-up specifically for untreated STIs is not
well reported.
Integration of ASP activities into routine ED practices may be challenging in settings of high
patient volume and limited personnel, especially for discharged patients where challenges in follow-up
occur. Utilizing pharmacy trainees (e.g., residents) or non-ED personnel may be required in some
institutions. Currently, our institutional model for follow-up of discharged ED patients with positive
cultures is driven primarily by administrative support staff and cross-cover physicians. Potential areas
for optimization were identified including delay in time to review and desire for stewardship expertise
in the process using an interdisciplinary approach. Thus, a pilot pharmacist-driven culture and RDT
follow-up program was implemented in November 2018.
2. Materials and Methods
2.1. Study Setting
This study took place at a tertiary teaching hospital ED, which had approximately 95,000 patient
visits in 2018. At this institution, ED pharmacists are involved in antimicrobial decision support
regarding cultures only when prompted by physicians prior to patient discharge. The current
culture follow-up practice for patients discharged from the ED involves communication among ED
administrative support staff (two individuals without formal clinical training) and physicians. The
administrative support staff are notified of all positive cultures and STI results for patients discharged
from the ED. All positive results that return during the previous 24 h are reviewed by the administrative
staff and acted upon the following morning. This staff review identifies discrepancies that may require
outpatient follow-up and brings these specific cases to the attention of the covering ED physician.
For cultures, the staff primarily interpret upon finalization of the culture and identify discrepancies,
including a ‘bug–drug’ mismatch with the prescribed antimicrobial and the susceptibility report or no
antimicrobial prescribed for the positive culture. Positive STI RDT which was not empirically treated
in the ED is also identified by the staff and brought to the physician for review. The covering physician,
who also has acute patient responsibilities in the ED, is tasked to review the cases selected by the staff
and communicate the intervention plans to the staff each morning. The staff then contact the patient
to carry out the outpatient follow-up. If the patient is not able to be contacted via telephone, a final
attempt to contact the patient is made through mailing of a letter.
Through implementation of a pharmacist-driven workflow, a PGY-1 pharmacy resident with
antimicrobial stewardship training implemented a live-alert system through an integrated clinical
decision support software (TheraDoc® ) for all culture and STI RDT updates and reviewed these results
daily for patients who were discharged from the ED. A background and training with the antimicrobial
stewardship and support team provided the confidence and expertise for the pharmacy resident

Pharmacy 2020, 8, 72

3 of 9

to review and triage results through the alerts, identify discrepancies that may require outpatient
follow-up, comprise a recommendation with the ED pharmacist, and communicate and implement a
plan in collaboration with the ED physician. The recommendations were based on local antimicrobial
prescribing guidelines, produced by the local antimicrobial stewardship and support team, and national
clinical management guidelines, when available. The pharmacy resident executed the follow-up plan
that was agreed upon by the physician, ED pharmacist, and pharmacy resident. A representation of
the pharmacists’ workflow during the pilot culture follow-up program is located in Appendix A. The
pilot, pharmacist-driven program was executed from 19 November 2018 through 15 February 2019.
2.2. Study Design
This was an IRB-approved, single-centered, pre- and post-implementation cohort study. Cultures
drawn during the pilot period were classified as the post-implementation group. The comparator
group, i.e., the observational pre-implementation group, included cultures drawn during the 90 days
prior to implementation (21 August 2018 through 18 November 2018). All positive urine, blood,
wound, and stool cultures and positive STI RDT for Neisseria gonorrhoeae, Chlamydia trachomatis, and
Trichomonas vaginalis which originated in the ED were screened for inclusion. Patients aged ≥18 years
who were discharged from the ED with positive cultures and/or positive STI RDT and for which an
outpatient follow-up was attempted were included in the study. Patients who expired in the ED, were
admitted to the hospital, or transferred to another institution were excluded.
The primary endpoints were time from ED discharge to result review and time from ED discharge
to completion of outpatient follow-up. Secondary endpoints included time from ED discharge to time
to first patient contact attempt, percentage of patients who had a repeat ED encounter within 30 days of
the index encounter, percentage of patients who were admitted within 30 days of the index encounter,
and antimicrobial prescribed during outpatient follow-up.
Descriptive statistics were used to characterize patients and culture types. The primary endpoints
of time to result review and time to outpatient intervention completion were analyzed using the
Wilcoxon signed-rank test. Chi-square or Fisher’s exact tests were used to examine the differences
in secondary outcomes in the pre- and post-intervention groups. An a priori sample size calculation
concluded that 157 patients were required to provide 95% power to detect a 20% difference in the
primary endpoint of time to review of positive culture or STI RDT.
3. Results
Of the 3757 patients discharged from the ED with cultures obtained, 127 patients were included—64
patients in the pre-implementation group and 63 patients in the post-implementation group (Figure 1).
The primary reason for exclusion (n = 337) was that outpatient follow-up was not required as initial
ED treatment plan was appropriate based on culture and/or STI RDT result (i.e., patient empirically
treated for STI in the ED, pathogen on culture susceptible to discharge antimicrobial and discharge
antimicrobial dosing and duration sufficient, etc.). Baseline characteristics are summarized in Table 1.
The most common result type was urine cultures (63.6%), followed by STI RDT (30.2%). Most patients
were not prescribed an antimicrobial upon ED discharge (pre, 59.4% vs. post, 60.3%).
Time-to-event data are summarized in Figure 2. The mean time to result review and mean time to
first attempt at patient contact were significantly reduced in the pharmacist-driven program by 27.3 h
and 17.4 h, respectively (75.2 h vs. 47.9 h, p < 0.001; 79.7 h vs. 62.3 h, p = 0.005). The mean time to
completion of outpatient intervention decreased, although this was not statistically significant (110.7 h
vs. 89.4 h, p = 0.114).
As demonstrated in Table 2, the most frequent intervention for both groups was initiation of active
therapy (39.1% vs. 30.2%, p = 0.39), followed by modification of previously prescribed therapy (37.5%
vs. 22.2%, p = 0.09). The post-implementation group had a significantly higher rate of sending a letter as
a final outpatient intervention attempt than the pre-implementation group (4.7% vs. 19.1%, p = 0.026).
Among patients who had initiation or modification of previously prescribed therapy, there was a
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significant reduction in proportion of patients prescribed a fluoroquinolone in the post-implementation
group (15.6% vs. 3.2%, p = 0.036). Rates of prescribing for other antimicrobials and classes were similar,
as demonstrated
Figure
3.
Pharmacy
2020, 8, x FOR in
PEER
REVIEW
2 of 10

1

Blood, stool, urine, or wound culture
2
3

Gonorrhea or chlamydia

21 August 2018–15 February 2019

Figure
1. Screening
andand
Enrollment.
Figure
1. Screening
Enrollment.
Table
Baseline
Characteristics.
Time-to-event data are summarized
in1.Figure
2. The
mean time to result review and mean time
to first
attempt
at
patient
contact
were
significantly
reduced
in
the pharmacist-driven
Baseline Characteristic, n (%)
Pre-Implementation, n = 64
Post-Implementation,
n = 63 program
p-Valueby
27.3 hours
and 17.4 hours, respectively (75.2 hours vs. 47.9 hours, p < 0.001; 79.7 hours vs. 62.3 hours,
Mean age, years (standard
50.67
(23.4)
42.40 (24.0)although this was
0.028not
p = 0.005). Thedeviation)
mean time to completion of
outpatient
intervention decreased,
Female
gender
51
(79.69)
51
(80.95)
1
statistically significant (110.7 hours vs. 89.4 hours, p = 0.114).
Result type
46 (71.9)
36 (57.1)
15 (23.4)
24 (38.1)
3 (4.7)
3 (4.8)
Antibiotic
provided
upon
ED
discharge
REVIEW
Nitrofurantoin
4 (6.3)Δ=27.31h (36.3%), p-value
7 (11.1)
<0.001
Sulfamethoxazole/trimethoprim
9 (14.1)
3 (4.8)
Clindamycin
0
1 (1.6)
Metronidazole
9 (14.1)
6 (9.5)
No antibiotic
38 (59.4)
38 (60.3)
TIME TO FIRST
PATIENT
Other
1 (1.6)
0
CONTACT
ATTEMPT
Beta-lactam
1 (1.6)
2 (3.2)
Δ=17.42h (21.9%) p-value=
0.00528
Fluoroquinolone
2 (3.1)
4 (6.4)
Urine
PCR/molecular testing 1
BloodTO
cultures
TIME
RESULT

0.17

75.18

47.87

0.35 2

79.72

62.3

0.62
0.44

1

RDT for N. gonorrhoeae, C. trachomatis, and T. vaginalis. 2 p-value evaluating for differences in the following
antimicrobials as a group: nitrofurantoin, sulfamethoxazole, clindamycin, metronidazole, other antimicrobial,
TIME TO prescribed. Beta-lactam and fluoroquinolones were excluded from this specific analysis and
and no antimicrobial
p-values
comparing these groups of antimicrobials are listed.
INTERVENTION

110.67

89.4

COMPLETION

0

Δ=21.27h (19.2%) p-value= 0.114

50
100
Hours post-ED discharge

Grey: pre-implementation; blue: post-implementation.
Figure 2. Time-to-event data.

150

Figure 1. Screening and Enrollment.

Time-to-event data are summarized in Figure 2. The mean time to result review and mean time
to first attempt at patient contact were significantly reduced in the pharmacist-driven program by
27.3 h and 17.4 h, respectively (75.2 h vs. 47.9 h, p < 0.001; 79.7 h vs. 62.3 h, p = 0.005). The mean time
Pharmacy
2020, 8, 72
5 of 9
to
completion
of outpatient intervention decreased, although this was not statistically significant
(110.7 h vs. 89.4 h, p = 0.114).

75.18

TIME TO RESULT
REVIEW

47.87

∆=27.31h (36.3%), p-value <0.001

79.72

TIME TO FIRST PATIENT
CONTACT ATTEMPT

Pharmacy 2020, 8, x FOR PEER REVIEW

3 of 10

62.3

∆=17.42h (21.9%) p-value= 0.00528
As demonstrated in Table 2, the most frequent intervention for both groups was initiation of
active therapy (39.1% vs. 30.2%, p = 0.39), followed by modification of previously prescribed therapy
TO The post-implementation group had a significantly
(37.5% vs. 22.2%, p =TIME
0.09).
110.67 higher rate of sending
INTERVENTION
a letter as a final outpatient intervention attempt than the pre-implementation group (4.7% vs. 19.1%,
COMPLETION
89.4
∆=21.27h
(19.2%)therapy,
p-value= there
0.114
p = 0.026). Among patients who had initiation or modification of
previously
prescribed
was a significant reduction in proportion of patients prescribed a fluoroquinolone in the postimplementation group (15.6% 0
vs. 3.2%, p = 0.036).50
Rates of prescribing
for other antimicrobials
100
150 and
classes were similar, as demonstrated in Figure 3.

Hours post-ED discharge

Table 2. Types of outpatient interventions.
Grey: pre-implementation; blue: post-implementation.
Type of Intervention, n (%)

Pre-Implementation, n = 64

Post-Implementation, n = 63
Figure
Figure2.2.Time-to-event
Time-to-eventdata.
data.

Initiation of therapy

25 (39)

p-value

19 (30.2)

0.39

Table 2. Types of outpatient interventions.

Modification of therapy
Type of Intervention, n (%)
Contact primary care provider
Initiation of therapy
Modification
of home
therapy
Contact
nursing
Contact primary care provider
1
Contact
nursing home
No medication
No medication 1
Lettersent
sent
Letter

24 (37.5)
Pre-Implementation, n = 64
4 (6.3)
25 (39)
24 (37.5)
5 (7.8)
4 (6.3)
5 (7.8)
5 (7.8)
5 (7.8)
3 (4.7)
3 (4.7)

14 (22.2)
0.09
Post-Implementation, n = 63
8 (12.7)
0.35
19 (30.2)
14
(22.2)
7 (11.1)
0.74
8 (12.7)
5 (7.9)7 (11.1)
1
5 (7.9)
12 (19)12 (19)
0.026

p-Value
0.39
0.09
0.35
0.74
1
0.026

1

Interventions
that resulted
in contact
with patient
no change
or initiation
newtherapy.
therapy.
Interventions
that resulted
in contact
with patient
with with
no change
or initiation
ofofnew

Prescriptions (%)

1

22

18

15
5

19
13

11
5

22
1

19
11

5

0

14
9

Antimicrobial
Pre-Implementation (n=55)

Post-Implementation (n=37)

The difference in fluoroquinolone prescribing was statistically significant (p < 0.05).
Figure
3. Medications
Prescribed
During
Outpatient
Follow-Up.
Figure
3. Medications
Prescribed
During
Outpatient
Follow-Up.

The proportion of patients who had a repeat ED encounter within 30 days was 10/64 (15.6%) in
the pre-implementation group and 12/63 (19.1%) in the post-implementation group (p = 0.78) (Table
3). Of the 10 patients who experienced a repeat ED encounter in the pre-implementation group, five
cases were related to the index ED encounter, with no related cases in the post-implementation group.
The proportion of patients who experienced a hospital admission within 30 days in the pre-
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The proportion of patients who had a repeat ED encounter within 30 days was 10/64 (15.6%)
in the pre-implementation group and 12/63 (19.1%) in the post-implementation group (p = 0.78)
(Table 3). Of the 10 patients who experienced a repeat ED encounter in the pre-implementation group,
five cases were related to the index ED encounter, with no related cases in the post-implementation
group. The proportion of patients who experienced a hospital admission within 30 days in the
pre-implementation group was 6/64 (9.4%) and in the post-implementation group was 5/63 (7.9%)
(p = 1.0). Of the six patients in the pre-implementation group who experienced a hospital admission,
two admissions were related to infection, and of the five patients who experienced a hospital admission
in the post-implementation group, one admission was related to infection. For the pre-implementation
group, one patient was admitted intentionally as a result of the outpatient intervention and three
patients were admitted for this reason in the post-implementation group. The reason for intentional
admission for these patients was positive blood cultures requiring further evaluation and intravenous
antibiotics. The time to intentional admission was 2.3 days in the pre-implementation group and 0.8
days in the post-implementation group.
Table 3. Repeat ED Encounters and Hospital Admissions.
Outcome, n (%)
Patients with repeat ED encounter
within 30 days
Patients with repeat ED encounter
related to index case
Patients with hospital admissions within
30 days
Patients with unintended repeat hospital
admission related to index case

Pre-implementation, n = 64

Post-implementation, n = 63

p-Value

10 (15.6)

12 (19.1)

0.783

5 (7.3)

0

–

6 (9.4)

5 (7.9)

1

2 (2.9)

1 (1.7)

–

4. Discussion
This study demonstrated a 36.3% reduction in time to result review with a pharmacist-driven
program for culture follow-up in the ED when compared to the administrative staff-physician
collaborative driven model. This impact can be attributed both to the live-alert workflow, the
confidence and knowledge of RDTs and interpretation of results performed by a pharmacist to
make decisions and recommendations to the ED provider based on preliminary culture results. This
reduction in time to result review led to a reduction in time to first patient contact attempt and time to
intervention. Although the 19.2% reduction in time to intervention was not statistically significant,
there may be clinical significance of this 21-h reduction in time to intervention. Of the 22 patients who
experienced a repeat ED encounter, 11 occurred within seven days of the index encounter discharge.
For these patients, time to repeat ED encounter ranged from 13.1 to 163.2 h. A 21-h reduction in time to
intervention could be impactful in reducing ED visits.
Positive STI results comprised 31.3% of all positive results reviewed during the study period, and
30.7% of all positive results requiring outpatient intervention. This finding highlights a potential missed
opportunity for empiric STI treatment(s) during the initial ED encounter in select high-risk patients per
the Centers for Disease Control and Prevention (CDC) guideline recommendations [15]. The practice of
withholding treatment for STIs until results are obtained often leads to limited treatment options (e.g.,
limited to oral prescriptions) or inability to connect with the patient for follow-up, especially among
patients seeking primary care in the ED. Additionally, the post-implementation group had 14.7% more
outpatient follow-ups due to a PCR/molecular testing result. As this is the method for STI testing that
was consistently used across the time of the study as it became the standard testing modality for STIs
prior to this study, this may indicate an increased rate of withholding empiric STI treatment.
A significantly higher proportion of patients in the post-implementation group were not able to
be reached after several telephone attempts (at a minimum, two telephone calls were attempted), and
therefore required a letter to be sent to the patient’s residence for an attempt at outpatient follow-up
(4.7% vs. 19%, p = 0.026). Other published studies suggest that the rate of unsuccessful patient contact
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via telephone ranges from 7% to 57% [16]. There are certain confounders that could have contributed to
the difference demonstrated in this study, including the daily time frame during which patient contact
is attempted and the lack of a consistent workspace and telephone. The lack of a designated phone
and the inconsistency of the pharmacy resident’s workspace could have potentially contributed to the
decreased success in patient contact by telephone. The allocation of a designated pharmacist for this
process and development of this pilot into a permanent workflow could address this issue.
There were no significant differences noted in outcomes related to repeat ED encounters and
hospital admissions within 30 days between the two groups (Table 3). Due to the constraints of the study
period, the comparative numbers were relatively low, with a total of 22 patients experiencing a repeat ED
encounter and 11 patients experiencing a hospital admission. When evaluating the reasons for repeat
hospital encounters and hospital admissions, there were fewer patients in the post-implementation
group who had subsequent events that were related to the index case (similar chief complaint).
Although it is difficult to draw conclusions from this small subgroup of patients, these results may
signal a longer study period and more robust comparisons may show that pharmacist-performed
follow-up helps prevent repeat ED encounters and hospital admissions related to the index case.
The pharmacist-driven approach also demonstrated a significant reduction in prescribing of
fluoroquinolones during outpatient follow-up. Fluoroquinolone prescribing occurred exclusively for
the patient population with positive urine cultures. Per Infectious Disease Society of America’s (IDSA)
guidelines and the local antimicrobial prescribing guidelines, fluoroquinolones should be reserved
for patients with signs and symptoms of pyelonephritis, such as fever >38 ◦ C and unilateral back
or flank pain. This reduction in fluoroquinolone prescribing can be explained by the addition of
a thorough chart review and recommendation by a pharmacy resident with stewardship training
and experience. Prior to the introduction of a pharmacist-driven, multidisciplinary approach, a
physician was the sole clinician responsible for chart review and the outpatient follow-up plan for
identified cultures across the three hospital system, potentially contributing to over prescribing
of fluoroquinolones (such as for acute cystitis and asymptomatic bacteriuria). This pilot led the
implementation of active, formal ASP activity in the ED. Prior to this pilot, ASP activities centered
around education on local prescribing guidelines and resistance scores [17,18]. While providers,
predominantly residents, are educated on these resources, they are not required to use them, which
may limit their effectiveness. Active and patient-specific incorporation of these resources through ASP
activities such as pharmacist-driven culture follow-up will be needed to impact change in antibiotic
utilization. Furthermore, the implementation of this pilot relied on a pharmacy resident to carry out
daily review and interventions. The results of this study highlight the capacity of a pharmacy trainee
to conduct ASP activities and support the reframing of resources for longitudinal ASP activities in the
ED, a possible new avenue for a pharmacy resident’s clinical experiences.
Limitations of this study include the lack of resources available for execution of the pilot, the
small sample size, that pharmacist time spent during the pilot was not studied, and that power criteria
were not met. The sample size could have been expanded to include cultures across the three campus
systems and a longer time interval to conduct the pilot if there was additional pharmacist support
and information technology support allocated to the pilot. Unfortunately, pharmacist time spent
during the pilot was not examined, limiting the ability to determine an appropriate proportion of this
responsibility to designate to a new or existing pharmacy service. It was difficult to accurately measure
time spent during the pilot due to the segmented approach to patient care due to other daily patient
care responsibilities, which were triaged daily by the pharmacy resident. The pharmacy resident
estimates approximately six additional hours of work per week designated to the pilot.
5. Conclusions
Introduction of a pharmacist-driven culture and STI test follow-up program in the ED at a
tertiary teaching hospital executed by a pharmacy resident demonstrated a reduction in time to result
review and intervention. Additionally, fluoroquinolone prescribing was significantly reduced for
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patients with positive urine cultures. Full implementation of a pharmacy service could optimize
stewardship initiatives and improve antimicrobial selection through the addition of a pharmacist
trained in stewardship.
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